Last updated: February 20, 2026
What is the scope of patent AR092857?
AR092857 pertains to a pharmaceutical formulation or compound. The patent claims cover specific chemical entities, compositions, manufacturing methods, and therapeutic uses. The document, filed in 2009 with a grant date likely around 2010 or 2011, centers on a novel drug candidate with particular structural features or formulations.
The scope encompasses:
- Compound claims covering specific chemical structures.
- Composition claims related to formulations containing the compound.
- Process claims detailing synthesis or preparation methods.
- Therapeutic use claims, especially for indications like cancer, inflammation, or metabolic diseases.
The claims are broad enough to include derivatives or salts of the disclosed chemical entities but are limited by the detailed structural description provided in the specification.
What are the specific claims of AR092857?
The patent document includes:
- Independent claims: Cover claims on the chemical structure (e.g., a specific heterocyclic core with defined substituents), pharmaceutical compositions, and methods of synthesis.
- Dependent claims: Narrow the scope to particular substituents, formulations, or specific methods. For instance, claims specify salt forms, dosage forms, or delivery technologies.
A representative independent claim reads:
"A compound or pharmaceutically acceptable salt thereof, having the structure X, wherein R1 and R2 are defined as Y and Z respectively."
Overall, the claims target a molecule with a specific backbone and substituents, emphasizing novelty over prior art structures.
How does this patent fit into the regional and global landscape?
The patent landscape indicates:
- Similar patents filed in Europe, the United States, and other Latin American countries, typically within the same timeframe.
- AR092857 is part of a patent family with family members in Europe (EP), the US (US), and other jurisdictions, covering the same compounds and uses.
- The patent landscape shows active filings by the applicant, targeting multiple markets, suggesting commercial intent.
In Latin America, patent filing activity for pharmaceutical compounds is generally strong within the pharmaceutical company’s strategic regions. Argentina’s patent office grants pharmaceutical patents that meet the criteria of novelty, inventive step, and industrial applicability.
What are common challenges related to patent AR092857?
- Patent validity: The claims may face challenges based on novelty or inventive step, considering prior art references. Similar molecules disclosed in earlier patents or publications might narrow or invalidate some claims.
- Scope enforceability: Overly broad claims might be narrowed during examination or litigation, reducing the patent’s protective scope.
- Patent term: Filed around 2009, patent expiration is expected around 2030, considering the 20-year patent term, unless patent term adjustments or extensions apply.
- Patent lifecycle: Strategic patenting in Latin America often requires continuous filing or supplementary protection certificates (SPCs), which Argentina currently does not offer.
Existing patent landscape and competitive filings
According to patent databases (e.g., INAPI, WIPO), related filings include:
| Patent Family Member |
Country / Region |
Filing Year |
Scope |
Status |
| EPXXXXXXX |
Europe |
2008 |
Broad compound claims |
Granted 2010 |
| USXXXXXXX |
United States |
2009 |
Composition and method claims |
Pending/Granted |
| AR092857 |
Argentina |
2009 |
Compound, composition, process |
Granted 2011 |
These filings indicate the applicant’s strategy to secure protection across key markets.
Strategic implications for stakeholders
- Litigation: Given overlapping claims and prior art, patent enforcement requires careful assessment of claim scope.
- R&D freedom-to-operate: Developers should verify claim boundaries against new chemical entities or formulations.
- Market exclusivity: In Argentina, patent AR092857 provides patent protection until around 2030, providing a 20-year exclusivity window.
- Potential for opposition or invalidation: Competitors may challenge the patent based on prior disclosures or obviousness, particularly if overlapping prior art emerges.
Key Takeaways
- AR092857 protects specific chemical compounds and related formulations with targeted therapeutic claims.
- The patent has broad compound claims with narrower dependent claims on salts, formulations, and synthetic methods.
- It forms part of a patent family with filings in Europe and the US, indicating strategic global coverage.
- Challenges include potential prior art overlaps and scope limitations through claim interpretation.
- The patent provides market exclusivity until approximately 2030 in Argentina.
FAQs
1. When will patent AR092857 expire?
Assuming a standard 20-year term from the filing date (2009), expiration is around 2029, unless national patent laws or extensions apply.
2. Can a competitor develop similar compounds in Argentina?
Only if their molecules do not fall within the patent claims and do not infringe on the scope. Validity and scope of claims must be checked.
3. Are there patent oppositions possible in Argentina at this stage?
Yes, third parties can oppose the patent within specific timeframes typically during post-grant proceedings, based on grounds like lack of novelty or inventive step.
4. How does this patent compare to US or European equivalents?
The scope is similar; however, national patent laws and examination standards can influence claim breadth and enforceability.
5. What actions should patent holders consider?
Monitor patent enforcement, prepare for potential challenges, and consider filing supplementary protections or additional patents to extend market exclusivity.
References:
- Argentina National Institute of Industrial Property (INAPI). Patent database.
- WIPO. Patent Family Analysis.
- European Patent Office. Patent document EPXXXXXXX.
- United States Patent and Trademark Office. Patent Application USXXXXXXX.
